ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2025-10-24 01:45Core Insights - On October 23, Zhifei Biological experienced a 0.25% decline in stock price with a trading volume of 305 million yuan [1] - The company reported a net financing outflow of 450.14 million yuan on the same day, with a total financing and securities balance of 1.507 billion yuan [1][2] - For the first half of 2025, Zhifei Biological's revenue was 4.919 billion yuan, a year-on-year decrease of 73.06%, and the net profit attributable to shareholders was -597 million yuan, a decrease of 126.72% [2] Financing and Securities - On October 23, Zhifei Biological had a financing buy-in of 39.17 million yuan and a financing repayment of 43.67 million yuan, resulting in a net financing buy-in of -4.50 million yuan [1] - The current financing balance is 1.503 billion yuan, accounting for 3.11% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - The company had a securities lending balance of 354.49 million yuan, which is above the 70th percentile level over the past year, indicating a high position [1] Shareholder and Institutional Holdings - As of September 19, the number of shareholders for Zhifei Biological was 135,900, a decrease of 2.59% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 36.35 million shares, a decrease of 10.59 million shares from the previous period [2] - The company has distributed a total of 7.318 billion yuan in dividends since its A-share listing, with 3.194 billion yuan distributed in the last three years [2]